PBMs Call Trump Drug Price Disclosure Rule Illegal

Pharmacy benefit managers are pushing back hard against President Trump's executive order requiring them to disclose drug pricing data to the public. PBMs are the middlemen who negotiate drug prices between insurance companies and pharmacies.

The proposed transparency rule stems from Trump's broader effort to lower prescription drug costs. Congress has also been targeting these intermediaries with new disclosure requirements as drug prices continue rising.

But the Trump administration recently rolled out a new proposed rule that would delay these transparency measures. This means drug pricing data will likely stay hidden from public view for the foreseeable future, according to industry reports.

PBMs like Express Scripts have suggested that drug companies should relaunch their products with lower list prices to help bring costs down. However, the companies are fighting any requirements to reveal their current pricing negotiations and rebate deals.

The battle reflects broader tensions over prescription drug costs, which remain a top concern for American families facing high out-of-pocket expenses.